Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: PRTA

Prothena Corporation plc

Healthcare | Biotechnology

No licensed closing price on file for PRTA. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-0.83

Prothena Corporation plc (NASDAQ: PRTA) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 16:48 UTC.

What Prothena Corporation plc does

Prothena is a clinical biotechnology company focused on developing treatments for neurodegenerative and rare amyloid diseases caused by protein dysregulation. The company advances a pipeline of therapeutic candidates, both wholly-owned and partnered with major pharmaceutical companies, targeting diseases including Parkinson's disease, ATTR amyloidosis, Alzheimer's disease, and ALS. Prothena has developed proprietary CYTOPE technology designed to target intracellular disease pathways in the brain and peripheral organs.

Summarized from Prothena Corporation plc’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-0.83

Revenue, margins & earnings

FY2021 Net income: $67MFY2021 Taxes & interest: $5MFY2021 Operating costs: $129M$201MFY2021FY2022: net loss $117M on revenue $54M$54MFY2022FY2023: net loss $147M on revenue $91M$91MFY2023FY2024: net loss $122M on revenue $135M$135MFY2024FY2025: net loss $244M on revenue $10M$10MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-15
  • 2026-10-1510% OwnerPurchase100,000$835.5K
  • 2026-10-1510% OwnerPurchase10,000$84.6K
  • 2026-10-0910% OwnerPurchase125,000$1.05M
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Prothena Corporation plc do?

Prothena is a clinical biotechnology company focused on developing treatments for neurodegenerative and rare amyloid diseases caused by protein dysregulation.

When did PRTA last file with the SEC?

Prothena Corporation plc's most recent SEC filing on record is a 8-K filed 2026-05-15. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 16:48 UTC. This page is also available as JSON at /api/data?ticker=PRTA and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for PRTA and 5,000+ tickers.

Create a free account — keep PRTA
For your agent
GET /api/data?ticker=PRTA

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt